Genetic Interactions That Predict Attention Deficit Hyperactivity Disorder Outcome and Severity
Posted Jan 16 2012 7:00pm
Description of Invention: Genotyping of attention deficit hyperactivity disorder (ADHD) linked chromosomal regions containing single nucleotide polymorphisms (SNPs) was used by researchers at the National Human Genome Research Institute (NHGRI) to discover gene interactions that increase the risk of developing ADHD and predict ADHD severity.
NHGRI researchers discovered an ADHD linked gene interaction between the latrophilin 3 (LPHN3) gene and a haplotype on chromosome 11q that contains the gene coding for the dopamine receptor D2 (DRD2) and neural cell adhesion molecule 1 (NCAM1). In a similar invention, mutations in LPHN3 were shown to increase the risk of developing ADHD (HHS E-312-2006, TAB 1504). Expanding on those findings, this invention describes an interaction between LPHN3 and 11q that not only doubles the risk of developing ADHD, but also the severity of ADHD. Furthermore, the LPHN3-11q interaction correlates with patient response to therapeutic treatments.
In summary, this invention can be used to develop biomarkers for determining susceptibility to and severity of ADHD, as well as, developing theranostic assays for determining prognosis of ADHD treatments. In addition, signaling pathways delineated from these genetic sites can be used to develop better ADHD therapeutics.
Applications:
Biomarkers for ADHD susceptibility and severity
Prognostic assays
Personalized treatment options
Advantages: Improved prediction of ADHD susceptibility, severity, and possibly patient response to treatment
Development Status:
Early-stage
In vivo data available (human)
Inventors: Maximilian Muenke (NHGRI) Mauricio Arcos-Burgos (NHGRI) Maria T Acosta (NHGRI)
For Licensing Information Please Contact: Charlene Sydnor Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: sydnorc@mail.nih.gov Phone: 301-435-4689 Fax: 301-402-0220
Description of Invention:
Genotyping of attention deficit hyperactivity disorder (ADHD) linked chromosomal regions containing single nucleotide polymorphisms (SNPs) was used by researchers at the National Human Genome Research Institute (NHGRI) to discover gene interactions that increase the risk of developing ADHD and predict ADHD severity.
NHGRI researchers discovered an ADHD linked gene interaction between the latrophilin 3 (LPHN3) gene and a haplotype on chromosome 11q that contains the gene coding for the dopamine receptor D2 (DRD2) and neural cell adhesion molecule 1 (NCAM1). In a similar invention, mutations in LPHN3 were shown to increase the risk of developing ADHD (HHS E-312-2006, TAB 1504). Expanding on those findings, this invention describes an interaction between LPHN3 and 11q that not only doubles the risk of developing ADHD, but also the severity of ADHD. Furthermore, the LPHN3-11q interaction correlates with patient response to therapeutic treatments.
In summary, this invention can be used to develop biomarkers for determining susceptibility to and severity of ADHD, as well as, developing theranostic assays for determining prognosis of ADHD treatments. In addition, signaling pathways delineated from these genetic sites can be used to develop better ADHD therapeutics.
Applications:
Advantages:
Improved prediction of ADHD susceptibility, severity, and possibly patient response to treatment
Development Status:
Inventors:
Maximilian Muenke (NHGRI)
Mauricio Arcos-Burgos (NHGRI)
Maria T Acosta (NHGRI)
Patent Status:
HHS, Reference No. E-187-2011/0
US, Application No. 61/505,864 filed 08 Jul 2011
Related Technologies:
US, Patent No. 8,003,406, Issued 23 Aug 2011, Reference No. E-312-2006/0
US, Application No. 60/850,972 filed 11 Oct 2006, Reference No. E-312-2006/0
Relevant Publication:
For Licensing Information Please Contact:
Charlene Sydnor Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: sydnorc@mail.nih.gov
Phone: 301-435-4689
Fax: 301-402-0220
Ref No: 2352
Updated: 01/2012